NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $76.90 +2.40 (+3.22 %) (As of 01/20/2019 04:00 PM ET)Previous Close$76.90Today's Range$73.90 - $77.0252-Week Range$64.08 - $127.77Volume261,643 shsAverage Volume213,997 shsMarket Capitalization$1.49 billionP/E Ratio22.10Dividend YieldN/ABeta0.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. Receive ENTA News and Ratings via Email Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA Previous Symbol CUSIPN/A Webwww.enanta.com Phone617-607-0800Debt Debt-to-Equity RatioN/A Current Ratio23.74 Quick Ratio23.74Price-To-Earnings Trailing P/E Ratio22.10 Forward P/E Ratio48.67 P/E GrowthN/A Sales & Book Value Annual Sales$206.63 million Price / Sales7.23 Cash Flow$3.7994 per share Price / Cash Flow20.24 Book Value$20.32 per share Price / Book3.78Profitability EPS (Most Recent Fiscal Year)$3.48 Net Income$71.95 million Net Margins34.82% Return on Equity21.56% Return on Assets20.35%Miscellaneous Employees113 Outstanding Shares19,420,000Market Cap$1.49 billion OptionableOptionable Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its earnings results on Monday, November, 26th. The biotechnology company reported $1.30 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.24 by $0.06. The biotechnology company had revenue of $67.20 million for the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. The company's revenue was down 11.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.86 EPS. View Enanta Pharmaceuticals' Earnings History. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Enanta Pharmaceuticals. What price target have analysts set for ENTA? 7 equities research analysts have issued 12 month price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' share price to reach $102.60 in the next year. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals. What is the consensus analysts' recommendation for Enanta Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals. Has Enanta Pharmaceuticals been receiving favorable news coverage? Media stories about ENTA stock have been trending neutral this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY) and Agios Pharmaceuticals (AGIO). Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the folowing people: Dr. Jay R. Luly, Pres, CEO & Director (Age 63)Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 67)Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)Ms. Carol Miceli, Director of Investor Relations Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Navellier & Associates Inc (0.15%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.03%) and Bowling Portfolio Management LLC (0.02%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Institutional Ownership Trends for Enanta Pharmaceuticals. Which institutional investors are selling Enanta Pharmaceuticals stock? ENTA stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC and Louisiana State Employees Retirement System. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Insider Buying and Selling for Enanta Pharmaceuticals. Which institutional investors are buying Enanta Pharmaceuticals stock? ENTA stock was bought by a variety of institutional investors in the last quarter, including Navellier & Associates Inc and State of Alaska Department of Revenue. View Insider Buying and Selling for Enanta Pharmaceuticals. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $76.90. How big of a company is Enanta Pharmaceuticals? Enanta Pharmaceuticals has a market capitalization of $1.49 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe. What is Enanta Pharmaceuticals' official website? The official website for Enanta Pharmaceuticals is http://www.enanta.com. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected] MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 249 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?